Revenue and Profit - The company's total revenue for 2023 is expected to be ¥174,876,443.46, a decrease of 10.38% compared to the previous year[6] - Net profit attributable to shareholders is projected at ¥11,726,670.74, down 70.90% year-on-year[6] - Basic earnings per share decreased to ¥0.16, representing an 80.49% decline compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period are estimated at ¥419,134,739.94, an increase of 0.35% year-on-year[5] - Shareholders' equity attributable to the company is expected to be ¥361,705,915.24, up 1.15% from the previous year[5] Expenses - Management expenses increased by ¥6,856,500 due to the completion of the JinHao Smart Medical Industrial Park and increased personnel[6] - R&D expenses rose by ¥7,990,000 as the company continues to invest in product development and talent acquisition[6] Impairment and Risks - The company recognized a credit impairment loss of ¥6,540,300 due to decreased customer demand and increased credit risk[6] - The decline in performance is attributed to global economic slowdown and reduced export trade growth[6] - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[8]
锦好医疗(872925) - 2023 Q4 - 年度业绩